The Long Run with Luke Timmerman
Timmerman Report
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
Mentioned books
Jun 22, 2022 • 59min
Ep116: Ivana Magovcevic-Liebisch on Precision Neuroscience
Ivana Magovcevic-Liebisch, CEO of Vigil Neuroscience, on precision neuroscience drug development.
Jun 7, 2022 • 59min
Ep115: Rahul Singhvi on Reimagining Biotech Manufacturing
Rahul Singhvi, CEO of Resilience, on rethinking the model for manufacturing of advanced biologics, gene and cell therapies.
May 23, 2022 • 1h 7min
Ep114: Chris Gibson on Industrializing Drug Discovery
Chris Gibson, co-founder and CEO of Recursion, on using new tools to industrialize drug discovery.
May 9, 2022 • 40min
Ep113: Lewis Cantley & Siddhartha Mukherjee on Fighting Cancer with Food and Drugs
Lewis Cantley and Siddhartha Mukherjee, co-founders of Faeth Therapeutics, on fighting cancer with food and drug combinations.
Apr 18, 2022 • 1h 6min
Ep112: Bernat Olle on Microbiome Therapeutics
Bernat Olle, CEO of Vedanta Biosciences, on developing microbiome therapeutics.
Mar 14, 2022 • 1h 3min
Ep111: Ray Stevens on Structural Biology-Driven Drug Discovery
Ray Stevens, CEO of ShouTi, on structural biology driven drug discovery.
Mar 1, 2022 • 1h 7min
Ep110: Michele Andrasik on Making Clinical Trials More Diverse
Michele Andrasik, a clinical health psychologist at the Fred Hutchinson Cancer Research Center, on improving community outreach and diversity in clinical trials.
Feb 15, 2022 • 1h 9min
Ep109: Derrell Porter on Cell Therapy Commercialization
Derrell Porter, CEO of CellEvolve, on a new approach to commercializing cell therapies.
Jan 31, 2022 • 1h 11min
Ep108: Praveen Tipirneni on Targeting Integrins With Small Molecules
Praveen Tipirneni, CEO of Morphic Therapeutic, on targeting integrins with small molecules.
Jan 11, 2022 • 1h 4min
Ep107: Bassil Dahiyat on Antibody Engineering & Company Building
Bassil Dahiyat of Xencor on antibody engineering and company building.
